8 unknown, 7 recruiting, 6 completed, 6 not yet recruiting. 22 Phase 2, 14 Phase 1, 4 Phase 3, 1 Not applicable.
Follow HER2-positive Gastric Cancer: new trials by email Literature Review of HER2-positive Gastric Cancer trials Research Report on HER2-positive Gastric Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA Zanidatamab - Esophageal Cancer, GastroEsophageal Cancer | Not yet recruiting | Jazz Pharmaceuticals | 300 | 2026-11-30 | 2026-10-26 | |
| Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study Zanidatamab, Oxaliplatin, Capecitabine - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 46 | 2026-07-01 | 2026-07-06 |
| A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer KN026, Capecitabine, Enlonstobart - HER2-positive Gastric Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 490 | 2025-12-30 | 2026-01-12 |
| JSKN003 Combined Treatment of HER2-positive Gastric Cancer JSKN003, KN026, Capecitabine - HER2-positive Gastric Cancer | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 153 | 2025-06-15 | 2025-05-31 |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab - HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | AstraZeneca | 840 | 2025-03-01 | 2026-10-16 |
| Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China Trastuzumab deruxtecan (T-DXd) - HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction | Recruiting | Daiichi Sankyo | 260 | 2025-02-27 | 2026-08-18 | |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer HLX22, Pembrolizumab, Trastuzumab - Gastroesophageal-junction Cancer, Monoclonal Antibody | Phase 3 | Recruiting | Shanghai Henlius Biotech | 550 | 2024-11-22 | 2026-02-27 |
| First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) Disitamab Vedotin, Sintilimab, S-1 - HER2-positive Gastric Cancer, Metastatic Gastric Cancer | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 110 | 2024-10-17 | 2026-09-15 |
| Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens Disitamab Vedotin(RC48) Plus Tratuzumab - HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Zhejiang Cancer Hospital | 35 | 2024-09-01 | 2024-08-27 |
| Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC Serplulimab, Trastuzumab, Oxaliplatin + Tegafur - HER2-positive Gastric Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 42 | 2024-07-15 | 2024-06-03 |
| RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer Disitamab Vedotin, Cadonilimab - HER2-positive Gastric Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 20 | 2024-07-06 | 2024-07-09 |
| ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer ELVN-002, Trastuzumab, 5-Fluorouracil - HER2-positive Breast Cancer, HER2-positive Gastric Cancer | Phase 1 | Active not recruiting | Enliven Therapeutics | 275 | 2024-05-30 | 2025-11-19 |
| Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease Experimental, Control - Gastric Cancer, HER2-positive Gastric Cancer | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 46 | 2024-03-01 | 2026-09-23 |
| Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer fruquintinib＋trastuzumab + XELOX - Gastric Adenocarcinoma, Gastric (Stomach) Cancer | Phase 1 / Phase 2 | Recruiting | Henan Cancer Hospital | 45 | 2024-02-22 | 2026-01-12 |
| 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study 89Zr-DFO*-trastuzumab PET scan - Breast Cancer, Metastatic Breast Cancer | Not applicable | Completed | Amsterdam UMC, location VUmc | 6 | 2023-06-26 | 2026-05-27 |
| Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Toripalimab, Trastuzumab, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) - Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction | Phase 2 | Active not recruiting | Yu jiren | 30 | 2023-05-30 | 2026-09-09 |
| Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC Disitamab Vedotin combined with fruquintinib and Tislelizumab - HER2-positive Gastric Cancer, Immunotherapy | Phase 1 / Phase 2 | Unknown | Fudan University | 43 | 2023-05-09 | 2023-08-09 |
| First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer Disitamab vedotin, Tislelizumab, S1 - HER2-positive Gastric Cancer | Phase 2 | Active not recruiting | Qilu Hospital of Shandong University | 55 | 2023-02-10 | 2025-02-07 |
| A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 XMT-2056 - HER2-positive Breast Cancer, HER2-positive Gastric Cancer | Phase 1 | Terminated | Day One Biopharmaceuticals, Inc. | 57 | 2023-01-24 | 2026-06-18 |
| [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors [68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2 expression - Esophageal Neoplasms, Gastric Neoplasms Malignant | Phase 2 | Unknown | Karolinska University Hospital | 72 | 2022-11-23 | 2022-11-30 |
Showing 20 of 37. Sign in to see all of them.
Stomach Neoplasms (13) · Breast Neoplasms (8) · Colorectal Neoplasms (5) · Neoplasm Metastasis (5) · Carcinoma, Non-Small-Cell Lung (4) · Endometrial Neoplasms (4) · Ovarian Neoplasms (4) · Urinary Bladder Neoplasms (4) · Esophageal Neoplasms (3) · Pancreatic Neoplasms (3) · Head and Neck Neoplasms (2) · Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Bile Duct Neoplasms (1)
Neoplasms by Site (16) · Digestive System Diseases (15) · Digestive System Neoplasms (15) · Gastrointestinal Diseases (15) · Gastrointestinal Neoplasms (15) · Neoplasms (15) · Stomach Diseases (13) · Breast Diseases (8) · Skin Diseases (8) · Skin and Connective Tissue Diseases (8) · Neoplastic Processes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Colonic Diseases (5) · Intestinal Diseases (5)
Trastuzumab (13) · Oxaliplatin (9) · Capecitabine (8) · Fluorouracil (5) · Cisplatin (3) · Paclitaxel (3) · S 1 (combination) (3) · disitamab vedotin (3) · pembrolizumab (3) · tislelizumab (3) · trastuzumab deruxtecan (3) · Drug Therapy (2) · Leucovorin (2) · Tegafur (2) · tucatinib (2)
Pieris Pharmaceuticals, Inc. (3) · Henan Cancer Hospital (2) · Qilu Hospital of Shandong University (2) · Shanghai JMT-Bio Inc. (2) · The First Affiliated Hospital of Zhengzhou University (2) · Acepodia Biotech, Inc. (1) · Amsterdam UMC, location VUmc (1) · AstraZeneca (1) · Bellicum Pharmaceuticals (1) · BioInvent International AB (1) · Carisma Therapeutics Inc (1) · Centre Hospitalier Universitaire de Besancon (1) · Daiichi Sankyo (1) · Day One Biopharmaceuticals, Inc. (1) · Enliven Therapeutics (1)
China (15) · United States (14) · South Korea (6) · Italy (5) · Germany (4) · Spain (4) · France (3) · Netherlands (3) · Poland (3) · Taiwan (3) · United Kingdom (3) · Argentina (2) · Australia (2) · Belgium (2) · Brazil (2)
Andres McAllister, MD, PhD (1) · Anthony Elias, MD (1) · Brad Sumrow, MD (1) · Caigang Liu, doctor (1) · Feng Wang (1) · Filippo Pietrantonio, MD (1) · Gordon Otto, MD, PhD (1) · Huifang Lv (1) · Jeanett Wetzel (1) · Jianjun Yang, Prof. (1) · Jieer Ying, M.D. (1) · Jiren Yu (1) · Jun Zhang (1) · Lian Liu, Doctor (1)
PMID 33263418, PMID 35340264, PMID 36441083, PMID 37991639, PMID 38548353, PMID 39726590, PMID 39920391, PMID 40200187, PMID 41071338, PMID 41811823
2023 (1)